Skip to main content
Print Save

Generic Alkindi Sprinkle Availability

Last updated on Mar 9, 2023.

Alkindi Sprinkle is a brand name of hydrocortisone, approved by the FDA in the following formulation(s):

ALKINDI SPRINKLE (hydrocortisone - granule;oral)

  • Manufacturer: ETON
    Approval date: September 29, 2020
    Strength(s): 0.5MG [RLD], 1MG [RLD], 2MG [RLD], 5MG [RLD]

Has a generic version of Alkindi Sprinkle been approved?

No. There is currently no therapeutically equivalent version of Alkindi Sprinkle available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Alkindi Sprinkle. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Composition comprising hydrocortisone
    Patent 9,649,280
    Issued: May 16, 2017
    Assignee(s): Diurnal Limited

    The disclosure relates to pharmaceutical compositions useful in the treatment of adrenal insufficiency in paediatric or elderly subjects.

    Patent expiration dates:

    • May 12, 2034
      ✓ 
      Patent use: TREATMENT OF ADRENAL INSUFFICIENCY
      ✓ 
      Drug product
  • Treatment of adrenal insufficiency
    Patent 9,675,559
    Issued: June 13, 2017
    Assignee(s): Diurnal Limited

    The disclosure relates to the treatment of adrenal insufficiency with particular but not limiting application to pediatric treatment regimens, the treatment of the elderly and non-human animals.

    Patent expiration dates:

    • January 10, 2033
      ✓ 
      Patent use: TREATMENT OF ADRENAL INSUFFICIENCY
  • Treatment of adrenal insufficiency
    Patent 9,717,740
    Issued: August 1, 2017
    Assignee(s): Diurnal Limited

    The disclosure relates to the treatment of adrenal insufficiency with particular but not limiting application to pediatric treatment regimens, the treatment of the elderly and non-human animals.

    Patent expiration dates:

    • November 19, 2032
      ✓ 
      Patent use: TREATMENT OF ADRENAL INSUFFICIENCY

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer